AUROPHARMA2021-07-012021-09-30in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2021-07-012021-09-30in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AUROPHARMA 2021-04-01 2022-03-31 2021-10-30 INR Lakhs Half yearly true Cash Flow Indirect Single segment Pharmaceutical Products 2021-07-01 2021-09-30 Unaudited Standalone 28831800000.00 823700000.00 29655500000.00 14021700000.00 58300000.00 1283600000.00 3892800000.00 34400000.00 981800000.00 6178100000.00 26450700000.00 3204800000.00 0.00 3204800000.00 1220400000.00 7600000.00 1228000000.00 0.00 1976800000.00 0.00 0.00 0.00 0.00 1976800000.00 -100000.00 1976700000.00 1976700000.00 0.00 585900000.00 1 3.37 3.37 0.00 0.00 3.37 3.37 NOTES: 1 The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. 2 The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 8 November 2021. The statutory auditors have carried out limited review of the above results for the quarter and half year ended 30 September 2021. An unmodified report has been issued by them thereon. 3 The Company operates in only one segment viz., 'Pharmaceutical Products'. 4 Sales of standalone include exports of Rs.214,045 lakhs for the current quarter (30 September 2020: Rs.406,508 lakhs). 5 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates. Single segment 2021-04-01 2021-09-30 Unaudited Standalone 57769300000.00 1263200000.00 59032500000.00 29456600000.00 117600000.00 166500000.00 8200500000.00 85000000.00 2128300000.00 12322700000.00 52477200000.00 6555300000.00 0.00 6555300000.00 2654800000.00 -227000000.00 2427800000.00 0.00 4127500000.00 0.00 0.00 0.00 0.00 4127500000.00 -16100000.00 4111400000.00 4127500000.00 0.00 585900000.00 1 7.04 7.04 0.00 0.00 7.04 7.04 Other Expenses 6178100000.00 Other Expenses 12322700000.00 9 The Board of Aurobindo Pharma Limited on 27 February 2021 had approved the transfer of its oral formulations business comprised in Unit 10 located at Multiproduct Special Economic Zone, Naidupet, Mandal, SPSR Nellore District, Andhra Pradesh to its wholly-owned subsidairy APL Healthcare Limited through a slump sale. During the previous quarter the above undertaking was transferred for consideration of Rs.131,500 lakhs. 10 The Board of Aurobindo Pharma Limited in their meeting held on 1st July 2021 approved the transfer of business undertaking comprised in Unit-4 of the Company located at Pashamylaram, Pattancheru Mandal, Sangareddy district, Telangana, to Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company. During the current quarter the above undertaking was transfered for consideration of Rs.93,850 lakhs. 11 The Board of Aurobindo Pharma Limited in their meeting held on 31st May 2021 approved Transfer of business undertaking comprised in Unit-16 of the Company located at TSIIC, SEZ, Polepally Village, Jadcherla Mandal, Mahbubnagar district, Telangana, to Wytells Pharma Private Limited, a wholly owned step-down subsidiary of the Company and 100% subsidiary of Eugia Pharma Specialities Limited. During the current quarter the above undertaking was transfered for consideration of Rs.29,415 lakhs. 12 The date of implementation of the Code of Wages 2019 and Code on Social Security, 2020 is yet to be notified by the Government. The Company is in the process of assessing the impact of these Codes and will give effect in the financial results when the Rules/Schemes thereunder are notified. 13 The Board has approved interim dividend @150% i.e.Re.1.50 (Rupee one and fifty paisa only) per equity share of Re.1 (Rupee One only) for the year 2021-22. 77300000.00 3281900000.00 1806400000.00 214600000.00 1490900000.00 10700000.00 0.00 3057900000.00 0.00 -3772000000.00 0.00 1235500000.00 0.00 2128300000.00 46500000.00 0.00 0.00 0.00 174800000.00 -387700000.00 0.00 0.00 0.00 -329100000.00 0.00 0.00 256200000.00 0.00 0.00 9292200000.00 15847500000.00 0.00 0.00 -243900000.00 3656000000.00 0.00 11947600000.00 0.00 0.00 1290200000.00 3199700000.00 0.00 0.00 0.00 0.00 13600000.00 4017000000.00 0.00 0.00 0.00 32400000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3215000000.00 0.00 0.00 0.00 0.00 28800000.00 0.00 0.00 0.00 -9131500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3040000000.00 0.00 88800000.00 880000000.00 44900000.00 0.00 0.00 -4053700000.00 -1237600000.00 10500000.00 -1227100000.00 3835800000.00 2608700000.00